The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy …

Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine
kinase, has served as a paradigm for successful application of molecularly targeted cancer …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …

For two decades, leukaemia stem cells (LSCs) in chronic myeloid leukaemia (CML) and
acute myeloid leukaemia (AML) have been advanced paradigms for the cancer stem cell …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] that …

Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …

The quest for treatment-free remission (TFR) and deep molecular response (DMR) in
chronic myeloid leukemia (CML) has been profoundly impacted by tyrosine kinase inhibitors …

Abstract Treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic
phase (CML-CP) is considered a feasible option, especially with the ability of second …

Background All studies of treatment-free remission (TFR) in patients with chronic myeloid
leukaemia have discontinued tyrosine kinase inhibitor (TKI) treatment abruptly and have …

Deregulated oxidative metabolism is a hallmark of leukaemia. While tyrosine kinase
inhibitors (TKIs) such as imatinib have increased survival of chronic myeloid leukaemia …